PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 December; 4(4): 506–513.
Published online 2003 October 17. doi:  10.1208/pt040464
PMCID: PMC2750657

Effect of shape of sodium salicylate particles on physical property and in vitro aerosol performance of granules prepared by pressure swing granulation method

Abstract

The purpose of this research was to investigate the effect of the shape of sodium salicylate (SS) particles on the physical properties as well as the in vitro aerosol performance of the granules granulated by the pressure swing granulation method. SS was pulverized with a jet mill (JM) to prepare the distorted particles, and SS aqueous solution was spray dried (SD) to prepare the nearly spherical particles. The particle size distribution, crushing strength, and pore size distribution of the granules were measured. The adhesive force of the primary particles in the granules was calculated according to Rumpf's equation. The in vitro aerosol performance of the granules was evaluated using a cascade impactor. Both JM and SD particles can be spherically granulated by the pressure swing granulation method without the use of a binder. The size of SD granules was smaller than that of JM granules. Although the crushing strength of the JM and SD granules is almost the same, the internal structures of JM granules and SD granules were found to differ, and the SD particles appear to have been condensed uniformly, resulting in a nearly spherical shape. In the inhalation investigation, the percentage of SS particles of appropriate size delivered to the region for treatment was noticeably higher for SD granules than for JM granules. This finding might be because the adhesive force of the SD primary particles was smaller than that of the JM primary particles in the granules and because the SD granules could be easily separated by air current to obtain the primary particles.

Keywords: pressure swing granulation, aerosol performance, particle shape, dry powder inhalation

Full Text

The Full Text of this article is available as a PDF (816K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M. Drug delivery to the respiratory tract using dry powder inhaler. Int J Pharm. 1994;101:1–13. doi: 10.1016/0378-5173(94)90070-1. [Cross Ref]
2. Geldart D. Types of gas fluidization. Powder Technol. 1973;7:285–292. doi: 10.1016/0032-5910(73)80037-3. [Cross Ref]
3. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm. 1994;102:127–132. doi: 10.1016/0378-5173(94)90047-7. [Cross Ref]
4. Clark AR. Medical aerosol inhalers: past, present, and future. Aerosol Sci Technol. 1995;22:374–391. doi: 10.1080/02786829408959755. [Cross Ref]
5. Steckel H, Muler B. In vitro evaluation of dry powder inhalers: influence of carrier particle size and concentration on in vitro deposition. Int J Pharm. 1997;154:31–37. doi: 10.1016/S0378-5173(97)00115-4. [Cross Ref]
6. Hinto T, Serigano T, Yamamoto H, Takeuchi H, Niwa T, Kawashima Y. Particle design of Wogon extract dry powder inhalation aerosols with gramulation method. Int J Pharm. 1998;168:59–68. doi: 10.1016/S0378-5173(98)00083-0. [Cross Ref]
7. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm. 1998;172:179–188. doi: 10.1016/S0378-5173(98)00202-6. [Cross Ref]
8. Keller M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Int J Pharm. 1999;186:81–90. doi: 10.1016/S0378-5173(99)00132-5. [PubMed] [Cross Ref]
9. Karhu M, Kuikka J, Kauppinen T, Bergstrom K, Vidgren M. Pulmonary deposition of lactose carriers used in inhalation powders. Int J Pharm. 2000;196:95–103. doi: 10.1016/S0378-5173(99)00450-0. [PubMed] [Cross Ref]
10. Staniforth JN, Rees JE. Electrostatic charge interactions in ordered powder mixes. J Pharm Pharmacol. 1982;34:69–76. [PubMed]
11. Davies PJ, Hanlon GW, Molyneux AJ. An investigation into the deposition of inhalation aerosol particles as a function of air flow rate in a modified “Kirk lung”. J Pharm Pharmacol. 1976;28:908–911. [PubMed]
12. Vidgren M, Karkkainen A, Karjalainen P, Paronen P, Nuutinen J. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm. 1988;42:211–216. doi: 10.1016/0378-5173(88)90177-9. [Cross Ref]
13. Nishii K, Ito Y, Kawashima N, Horio M. Pressure swing granulation, a novel binderless granulation by cyclic fluidization and gas flow compaction. Powder Technol. 1996;74:1–6. doi: 10.1016/0032-5910(93)80001-Q. [Cross Ref]
14. Mikami T, Kamiya H, Horio M. Numerical simulation of cohesive powder behavior in fluidized bed. Chem Eng Sci. 1988;53:1927–1940. doi: 10.1016/S0009-2509(97)00325-4. [Cross Ref]
15. Yuasa H, Higashi S, Ozeki T. Preparation of granules for dry powder inhaler by pressure swing granulation method and drug particle delivery. J Pharm Sci Technol Jpn. 2002;62:67–79.
16. Yuasa H, Higashi S, Ozeki T. Granulation for dry powder inhaler granules having low hardness by pressure swing granulation method and drug particle delivery in using several kinds of inhalation devices. J Japan Soc Pharm Machinery Eng. 2002;11:6–12.
17. Watanabe M, Ozeki T, Torii Y, Shibata T, Murakoshi H, Takashima Y, Yuasa H, Okada H. Preparation of two-drug composite granules for dry powder inhalation by pressure swing granulation method and evaluation of their in vitro aerosol performance to lung. J Pharm Sci Technol Jpn. 2003;63:148–157.
18. The Handbook of the Japanese Pharmacopoeia. 14th ed. Tokyo, Japan: Hirokawa Publishing Co; 2001:C1383–C1386.
19. The Handbook of the Japanese Pharmacopoeia. 14th ed. Tokyo, Japan: Hirokawa Publishing Co; 2001:B569–B576.
20. Rumpf H. Zur theorie der zugfestigkeit von agglomeraten bei kraftubertragung an kontaktpunkten. Chem Ing Tech. 1970;42:538–540. doi: 10.1002/cite.330420806. [Cross Ref]
21. Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Mimura K, Momose D, Ouchi K. A new spherically agglomerated drug composite system with lactose for dry powder inhalation. Adv Powder Technol. 2003;14:215–229. doi: 10.1163/156855203763593994. [Cross Ref]
22. Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Mimura K, Momose D, Ouchi K. A new agglomerated KSR-592 b-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo. J Control Release. 2003;88:23–33. doi: 10.1016/S0168-3659(02)00460-1. [PubMed] [Cross Ref]
23. Hino T, Serigano T, Yamamoto H, Takeuchi H, Niwa T, Kawashima Y. Assessment of inertial separation techniques used for pressurized metered dose inhalers to evaluate respiratory deposition of aerosolized Wogon extract dry powder in vitro. STP Pharmacia Sciences. 1997;7:307–314.
24. Pitcairn GR, Lankinen T, Seppala OP, Newman SP. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J Aerosol Med. 2000;13:97–104. doi: 10.1089/089426800418622. [PubMed] [Cross Ref]
25. Newman SP, Pitcairn GR, Adkin DA, Vidgren MT, Silvasti M. Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer. J Aerosol Med. 2001;14(2):217–225. doi: 10.1089/08942680152484144. [PubMed] [Cross Ref]
26. Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med. 2001;95:720–727. doi: 10.1053/rmed.2001.1107. [PubMed] [Cross Ref]
27. Harjunen P, Lehto VP, Martimo K, Suihko E, Lankinen T, Paronen P, Jarbvinen K. Lactose modification enhance its drug performance in the novel multiple dose Taifun DPI. Eur J Pharm Sci. 2002;16:313–321. doi: 10.1016/S0928-0987(02)00126-4. [PubMed] [Cross Ref]
28. Kinnarinen T, Jarho P, Jarvinen K, Jarvinen T. Pulmonary deposition of a budesonide/gamma-cyclodextrin complex in vitro. J Control Release. 2003;90:197–205. doi: 10.1016/S0168-3659(03)00176-7. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists